Researchers found its feasibility to inhibit tumor development via blocking PI3K/AKT/mTOR, which could be divided into PI3K inhibitor (AZD8835, CUDC907 and GDC0077), AKT inhibitor (ARQ092, AZD5363 and MK2206) and mTOR inhibitor (Ridaforolimus, Sirolimus and Evcrolimus); many of them have been proven to be safe and effective in clinical trials, and some of them, such as Zydelig, Copanlisib, Rapamycin and Sirolimus, have been approved for human cancer treatment by the FDA, except for application in tumor therapy. The gene discussed is AKT1; the disease is cancer.